Navigation Links
BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
Date:10/19/2010

s Reduced Innate Immune Stimulation by asiRNA Structure: Expanding Therapeutic Application of siRNA.

About Age-Related Macular Degeneration (AMD)

A leading cause of vision loss and blindness, AMD is a disease associated with aging that gradually destroys sharp, central vision. According to the National Eye Institute, age-related macular degeneration affects more than 1.75 million individuals in the United States alone. This number is expected to increase to almost three million by 2020.

About BioMolecular Therapeutics, Inc. (www.bmtlab.co.kr)

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.


'/>"/>
SOURCE BioMolecular Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the pharmaceutical, biotechnology, and ... United States, today announced its financial results for the ... Fourth-Quarter 2014 Highlights , Net Revenues Increased 21.3% ... Services Net Revenues Grew 17.7% Year Over Year to ...
(Date:3/5/2015)... Deutschland, 5. März 2015  Die amerikanische ... deutsche biopharmazeutische Unternehmen CureVac geben heute bekannt, ... Millionen US-Dollar) in CureVac investiert. CureVac ist ... Messenger-RNA (mRNA). Auf Basis dieses Moleküls entwickelt ... Krankheiten und zum Schutz vor Infektionskrankheiten. ...
(Date:3/5/2015)... , March 5, 2015  BioPhotas, Inc., an FDA ... use patented photo-therapeutic technologies to treat skin, muscle and ... the Semper Fi Fund to provide BioPhotas, flagship product, ... of pain management solutions.  Commenting on ... Marine who used the Celluma at the Warrior Hope ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3
... Help Survivors Start Exercise Routine Based on Current Cardiovascular ... of cancer survivors is not affected by many standard ... Medical Cancer. That is the finding of a ... American College of Sports Medicine in Seattle. "We ...
... Progression-Free Survival, Disease Control and Neurotoxicity Data To ... to Support Picoplatin as a Neuropathy-Sparing Alternative to ... Poniard Management Team to Host Analyst and Investor ... - SOUTH SAN FRANCISCO, Calif., May 28 ...
Cached Medicine Technology:Cardiovascular Fitness Not Affected by Cancer Treatment 2Cardiovascular Fitness Not Affected by Cancer Treatment 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 6
(Date:3/5/2015)... March 05, 2015 Rhode Island Medical Imaging ... in a row to support the Providence College (PC) women’s ... covered the purchase of the ‘Think Pink’ uniforms, which were ... East Conference opponent DePaul University at Alumni Hall/Mullaney Gymnasium in ... our support of the PC women’s basketball’s ‘Pink Out’ event,” ...
(Date:3/5/2015)... On March 2, 2015, NBC News ... the Rise, Plastic Surgeons Say,” that comments on the ... Aesthetic Plastic Surgery and the American Society ... year-over-year doubling of surgical butt augmentations performed in 2014. ... article, this increase can be attributed to the social ...
(Date:3/5/2015)... March 05, 2015 TCS Healthcare Technologies ... for the population health management arena, is pleased to ... management software, ACUITY Advanced Care™ (ACUITY) version 7.20. The ... performance and the advantages of automation. , The webinar, ... will be led by Jeff Frater, RN, BSN, Director ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Califia ... today announced at Natural Products Expo West that its ... now 100 percent soy and dairy free. Califia Farms ... serve bottle and are packed with six grams of ... that includes fiber, B vitamins and magnesium. , Protein ...
(Date:3/5/2015)... March 05, 2015 Taking center ... Fort Worth, Texas April 9-11th is IDRevolution hosted ... providing personalized nutrition. IDLife offers a variety ... This customized approach to vitamin supplementation is ... with a free HIPAA compliant online assessment and ...
Breaking Medicine News(10 mins):Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2
... ... back to a six year success story as a national retailer for ... since 2004 more and more requests have been received from nearly all ... and more shipped to the UK, USA and even Australia.,Strandkorb & Meer ...
... the Gulf of Mexico, and they are concerned about its potential ... from a continuing survey conducted by the University of Minnesota. ... conducted by The Food Industry Center at the U of M. ... were aware of the spill and 85 percent say they are ...
... drugs using gas bubbles and sound waves is to be ... highly toxic drugs to be delivered in small doses directly ... good use. If successful, the technique could easily be adapted ... chemists and cancer specialists from across the University to work ...
... the University of Kentucky,s College of Medicine have identified ... risk for Alzheimer,s disease that could prove important for ... by Brian Gold, associate professor of anatomy and neurobiology, ... majority of deep parts of the brain and consists ...
... Monday, June 28, 2010 In the first ever published ... live with their minor children, a team led by a ... of cancer survivors are parenting young children, highlighting a group ... today in Cancer , a peer-reviewed journal of the ...
... the University of Leicester have demonstrated that movable sequences of ... specific diseases, are far more common than previously thought. ... , Dr Richard Badge and his collaborators examined L1 (or ... genetic code around the genome. By breaking up genes, L1s ...
Cached Medicine News:Health News:Strandkorb & Meer Going to Exceed 20% of Total Sales Volume with International Business in 2010 2Health News:Strandkorb & Meer Going to Exceed 20% of Total Sales Volume with International Business in 2010 3Health News:Bursting bubbles with sound offers new treatments for cancer 2Health News:Bursting bubbles with sound offers new treatments for cancer 3Health News:Alzheimer's imaging study identifies changes in brain's white matter 2Health News:More than a million parents with minor children are cancer survivors 2Health News:'Copy-and-paste DNA' more common than previously thought 2
... Cortisol Range Verifiers have been validated for ... Immunodiagnostic Products Cortisol Reagent Pack and Vitros,Immunodiagnostic ... low and,high cortisol concentrations, close to the ... be used,to verify measurement of cortisol at ...
Rapid assay, results in 1 hours,Range 20-800 ng/mL; sensitivity 2.5 ng/mL,Can be used for animal sera; requires extraction protocol and steroid free serum...
... 1000 assays are designed for ... IMMULITE 1000, continuous random access ... in both design and operation. ... in a wide variety of ...
... XCAT 100 X-Ray System from KUBTEC is a ... two and three dimensional representation of the specimen ... reconstruction of specimen X-ray images, the micro focus ... level of detail in standard 2D images. The ...
Medicine Products: